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Background: Healthcare staff should be aware of the importance that patients may attach to 
the words that are used to convey information. This is relevant in terms of the patients’ under-
standing. Modeling how people understand the information conveyed in a medical context may 
help health practitioners to better appreciate the patients’ approach. 
Purpose: 1) Analyze the participants’ self-reported perception of the type of information 
provided in an oncological scenario in terms of three dimensions: impairment to their health, 
risks associated with the disease itself and commitment required to undergo the treatment; and 
2) show the benefits of using Rasch scaling for the analysis of the data. Starting from a survey, 
Rasch scaling produces a unidimensional logit-interval scale relating to the extent to which 
each item conveys a latent dimension. These were related to structure, in particular concerning 
communication by means of opposite vs. unipolar language.
Subjects and methods: The participants rated 82 items of information in a questionnaire 
regarding their perception of impairment to their health (H) and the risks (R) and commitment 
relating to the treatment prescribed (T). 
Results: The scaling produced an item bank for healthcare staff to consult in order to estimate 
the importance the recipient would be likely to attach to the vocabulary used and the likely 
impact of the information in terms of the patient’s condition. Furthermore, the use of opposites 
was generally associated with a clearer impression of whether the information given was gener-
ally only very negative or slightly negative, whereas ‘neutral’ information was often perceived 
as being very negative. 
Actual findings: Is possible to estimate people’s understanding more precisely (in terms of H, R 
and T) which can help healthcare practitioners to modulate the way they convey information. 
Limitations: The participants in the study were healthy volunteers and the context was 
simulated.
Keywords: Rasch model, simulated oncological scenario, perceived severity of impairment to 
health, perception of risk, perceived commitment to the treatment, opposites
Introduction
The WHO has defined the term “health” as “a state of complete physical, mental, 
and social well-being and not merely the absence of disease or infirmity” (July 22, 
1946). Over the years, modern medicine has increasingly abandoned the biomedical 
model of patient care (mainly centered on the study of symptoms and laboratory tests) 
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in favor of a bio-psychosocial model.1,2 Several studies3–5 
have shown that when patients are more involved in and 
“better informed” about the treatment of their condition, 
they are better able to manage their treatment plan. How-
ever, in a medical context, defining what “well informed” 
means is not easy at all as it involves assessing not only 
what a doctor says but what “the patient understands”. For 
example, it is known that 40%–80% of the information 
provided by the doctor is almost immediately forgotten by 
the patient or remembered incorrectly.6 This is probably 
one of the reasons why the percentage of patients who 
adhere to medical instructions varies about from 40% to 
90% and only half of all drugs are taken as per medical 
recommendation.7,8
The plethora of studies concerning doctor–patient 
communication9–15 can be roughly divided into three cat-
egories: descriptive studies, aimed at analyzing the content 
and the interaction process; correlational studies, in which 
the interaction between knowledge, comprehension, satis-
faction, and adherence to the treatment is evaluated; and 
intervention studies, which are centered on improving the 
skills of health care professionals. One aspect is, however, 
common to all these types of study, that is, the objective is to 
“appreciate and comprehend the patient’s perspective and his/
her behavior”.16 The objective of the present study (that can 
be ascribed to the first category) is also to provide evidence 
that in addition to content, certain specific characteristics of 
the structure itself of any communication can influence the 
degree of comprehension with the focus on the deliberate use 
of opposites. The results demonstrate the benefits of using 
a specific methodology (ie, Rash Models) in order to assess 
the relative weight (in terms of impact) that patients give to 
the terms used to communicate.
The impact of various types of 
information and the patient’s perception 
of the condition of their health
Various models have been put forward concerning the 
psychological factors which influence people’s decisions 
concerning their health.17,18 Perception of risk is one of the 
key factors.19–22 Some empirical assessments of individual 
beliefs and values regarding certain types of information 
and contexts have shown, for example, that the attitude 
of Italian citizens toward participating in clinical trials 
depends on whether a preventive intervention or the treat-
ment of a disease is involved. Less than 30% of participants 
said they would agree to participate in a trial involving a 
“vaccination” (ie, in a situation in which the person was 
not suffering from a disease and their perception was of 
low risk) and only 5% would give their permission for a 
younger relative to participate. In contrast, almost 50% 
indicated that they would agree to take part in a therapeu-
tic randomized clinical trial in a situation in which they 
had been diagnosed with a disease and a greater degree 
of risk was perceived.23,24 Several studies have found this 
bias toward omission.25–29 For instance, people prefer not 
to vaccinate their children against a potentially fatal case 
of influenza (ie, omission or inaction) even if this choice 
might represent a greater risk of death than the vaccination 
itself (ie, commission or action).26,30,31 Conversely, in cases 
involving diagnoses of cancer, people manifest a prefer-
ence for action26 since they feel a strong need to combat the 
disease. Information content (ie, influenza vs cancer and 
the presence/absence of disease or preventive intervention) 
is, therefore, a decisive factor from a psychological point 
of view, but another critical factor is the formatting of 
information.32–37 Studies aimed at finding ways to optimize 
people’s understanding in cases where informed consent 
is required have explored the impact of using multimedia 
(eg, graphics and visual aids, videos, bullet pointed texts, 
etc),38–40 as well as question and answer sessions or focus 
group discussions with nurses and/or doctors,41 and the use 
of techniques including varying the length and complexity 
of sentences42 and using bipolar or unipolar structures.43 The 
way in which information is structured in doctor–patient 
communication and how this impacts on the patient’s 
understanding has also been the subject of research which 
goes beyond the case of informed consent. For instance, 
Ong et al44 used the Roter Interaction Analysis System 
classification system45 to assess the impact of various dif-
ferent categories of information on patient satisfaction in 
oncological consultations. This methodology was also used 
by Ishikawa et al46 in a cancer study in Japan. In their study, 
Venetis et al47 showed that increasing the use of nominal-
ization, concrete nouns, and group nouns may be a good 
way to provide patients with more thorough information 
in a more accessible manner (the context in that case was 
patients with breast cancer). Robinson and Heritage48 stud-
ied the association between the format of doctors’ opening 
questions which prompt patients to present concerns and 
the patients’ post-visit evaluations of the relative affective-
relational dimension. Siminoff et al49 found that in order to 
optimize the degree of comprehension in patients, doctors 
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should structure their clinical encounters with a view to 
increasing the patient’s affective participation by means of 
encouraging them to ask questions and actively participate 
in the decision-making process.
In the present study, a simulated doctor–patient communi-
cation scenario was used to investigate both the psychological 
impact of various types of content in the context of oncological 
diagnosis and the effect of using a different communication 
format, namely, the inclusion of overt references to opposite 
poles (such as large vs small, common vs rare, or difficult 
vs easy to cure) as compared to unipolar communication in 
which opposite semantic anchors are not provided. The impact 
of these variations in content and structure was assessed in 
terms of the participants’ self-reported perception of 1) the 
condition of their health, 2) the risks pertaining to the dis-
ease and adhering to and completing the proposed treatment 
regimen, and 3) the commitment required to engage in and 
complete the treatment.
The impact of the information was assessed by means of 
self-reported perception rather than by observing its direct 
effect on psychological aspects such as decision making 
or the choice of treatment. Rasch models50,51 were used 
to analyze the response data. However, an evaluation of 
psychological aspects is also important, and the results of this 
study suggest a line of research and a type of methodology 
that can be easily extended to provide valuable information. 
For instance, Gavaruzzi et al52 found that decision making 
in a cancer scenario depends on the “perceived severity of 
the disease”, which in turn depends on how the patient has 
been informed about his/her condition, that is, whether the 
tumor is malignant or benign or is a benign tumor that could 
become malignant in the future or increase in size. This 
may also include advice about the type of treatment (ie, 
watchful waiting or surgery). The present study investigates 
more deeply the extent to which the patient perceives the 
severity of his/her condition. This was done by focusing on 
a set of information which includes some of the topics con-
sidered in Gavaruzzi et al’s study, but further aspects were 
also investigated relating to the nature of the disease, and the 
duration and side effects of the treatment and their impact 
on the patient’s quality of life. In particular, the research 
focused on three dimensions: the participant’s perception 
of the condition of his/her health (H), the degree of risk (R), 
and the degree of commitment relating to the treatment 
prescribed (T). The relationship among these three ratings 
was studied, and the effects of modulating the information 
by means of varying the structure of the communication 
were explored.
Understanding the type of information that leads to a 
disease being perceived as more severe in terms of these three 
psychological dimensions might make it easier for doctors to 
comprehend what lies beneath a patient’s decision regarding 
treatment. It might also help doctors and health practitioners 
to narrow the gap between how they communicate the gravity 
of a disease and how patients understand and evaluate the 
situation accordingly. We feel that the results of this study 
may also be helpful in the context of clinical trials as they 
show a promising way to address the recurrent concern 
that communications concerning informed consent need to 
be improved.36,53–57
The study
The study had three main aims. The first was to scale the 
information that was given to the participants in a simulated 
oncology scenario (conveyed by means of simple verbal 
statements constituting the “items” in the questionnaire). 
This referred to the nature of the disease or the character-
istics of the treatment, from its duration to the incidence of 
adverse side effects and any changes in terms of quality of 
life during and after treatment. These items were rated by the 
participants with reference to their subsequent perception of 
impairment to health (H), the risk inherent to the disease and 
the proposed treatment (R), and the commitment relating to 
engaging in the treatment (T). The “weight” of each verbal 
statement was obtained by applying the Rasch measurement 
model50,51 with the result expressed in logit scores along 
three different unidimensional scales (“Statistical analysis” 
section).
The second aim was to explore whether specific char-
acteristics relating to the structure of the communication 
were associated with significantly different locations along 
the three dimensions. In particular, we included three dif-
ferent types of items in our initial set: 1) items expressed 
in terms of opposite properties (eg, small nodule–large 
nodule, minor side effects–severe side effects); 2) items 
expressed quantitatively without any reference to opposites 
(eg, referring to the size of the nodule in centimeters or to 
the incidence of side effects in percentages); or 3) items 
expressed in a “neutral” way (eg, referring to the existence 
of a nodule or the existence of side effects without qualify-
ing or quantifying them). We assessed the relative impact 
of these various communication types by studying whether 
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the use of opposites affected the participant’s perception 
in any way. The decision to use “opposite properties” was 
based on the results of a previous study43 which indicated 
that people’s understanding and satisfaction with how 
information is conveyed is greater when opposites are 
used. Henceforth, this variable will be referred to as Com-
munication Type and the two relative levels as Bipolar 
communication (B) when opposites are used (eg, “The 
medical tests have revealed the presence of a small nodule”) 
and Unipolar communication (U) when opposites are not 
used (eg, “The medical tests have revealed the presence of 
a 0.5 inch nodule”). Secondly, we focused on Polarity in 
order to determine whether the items elicited significantly 
different responses depending on whether there was a refer-
ence to the very negative (VN) or slightly negative (SN) pole 
of the dimension concerned (eg, “The medical tests have 
revealed the presence of a large nodule”; “The medical tests 
have revealed the presence of a small nodule”) or whether 
there was no mention of either one pole or the other (neutral 
negative: NN, eg, “The medical tests have revealed the pres-
ence of a nodule”, with no reference to whether it is large 
or small). Thirdly, the effect of the presence or absence of 
quantified information was studied.58–60 Our initial set of 
items consisted of four different types of communication 
(ie, “numerically expressed” quantity (NM), eg, “1 in a 100”; 
“qualitatively expressed” quantity (QL), eg, the type of 
tumor is “common”; “vaguely expressed” quantity (VG), eg, 
“The duration of the adverse side effects varies over time”; 
and “no” quantity (NO), eg, “This treatment is administered 
on an inpatient basis”). The effect of this variable on the 
ratings given by the participants was evaluated.
The third main aim of the study was to obtain regression 
functions that would permit us to predict a participant’s 
responses for one dimension based on his/her responses for 
another dimension. For example, a doctor might start with 
a patient’s reaction to a specific item in one of the three 
dimensions (eg, risk, R) in order to predict his/her reaction 
to the same item in the other two dimensions (ie, perception 
of the condition of his/her health, H, and perception of the 
degree of commitment required, T).
From a methodological point of view, the application 
of Rasch models allowed us to reach these three main goals 
(“Statistical analysis” section).
Subjects and methods
Participants
Four hundred and seventy Italian undergraduate students 
(University of Verona, non-medical faculties) and their 
relatives participated voluntarily and anonymously in the 
study (297 F, 173 M; mean age 28.73, SD=9.11). Written 
informed consent was provided by each participant. We 
used this sample of subjects in order to maximize the impact 
of the type of information being given since it was made 
up of people who would not usually receive this sort of 
communication. The study complied with the Helsinki ethics 
protocol and was approved by the Ethics Committee of the 
University of Verona (where the data were collected).
Materials
A paper questionnaire consisting of 82 items (verbal state-
ments) was used. A scenario was described as follows: 
Imagine that your doctor has recommended that you have 
some medical tests at a center specialized in oncological 
diagnoses in order to ascertain whether or not you have a 
health problem. You have done the tests and now you are 
talking to the doctor who tells you what the situation is. 
During the interview, he/she gives you various pieces of 
information.
The 82 items which followed were each related to various 
pieces of information. The following are examples of the 
items presented: “Medical tests have shown the presence 
of a 0.5 inch long nodule”; “Medical tests have revealed 
the existence of a benign nodule”; “This type of tumor is 
common”; “This tumor is easy to treat”; “This treatment 
has a 70% efficacy rate”; “The standard treatment for this 
tumor has minor adverse side effects”; and “This treatment 
takes 15 days to complete”. The complete list of items is 
reported in Table S1.
Participants were asked to provide three ratings (on a 
scale ranging from 0 to 10) for each item, expressing their 
perception of the degree of impairment to Health (H), the 
Risks involved (R), and the degree of commitment required 
for the Treatment (T).
The items used in the questionnaire had been identified 
in a previous study,43 based on two sources: the information 
exchanged between doctors and patients in a series of videos 
simulating typical dialogues in diagnostic and follow-up 
consultations (produced by the psychology department and 
the medical staff of the Italian National Cancer Institute 
[Centro di Riferimento Oncologico in Aviano, Italy]) and 
information concerning the nature and incidence of side 
effects as commonly presented in standard informed consent 
forms. From a communicative point of view, three different 
structures were used: one that made reference to opposite 
properties, one that used quantitative expressions, and one 
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was “neutral” (ie, with no quantification or qualification in 
terms of opposites).
The order of the 82 items in the questionnaire and of 
the three response scales (H, R, T) was randomized among 
participants.
Procedure
The questionnaire was given to each participant, either during 
the University Open Day or during psychology lectures on 
topics unrelated to the subject of the study. The questionnaire 
was completed individually in a quiet room at the university. 
No fixed amount of time was established, but, on average, 
the participants took between 30 and 40 minutes to fill in 
the questionnaire.
statistical analysis
The ratings on the three response scales (raw data) were 
transformed by means of a Rasch analysis. The Rasch unidi-
mensional measurement model was used since it deals with 
responses as a function of the interaction between two quan-
titative latent dimensions, one concerning the characteristics 
of the “person” and another concerning the characteristics of 
the “items”.51,62–65 Their specific meaning depends on what 
is being assessed. For example, in an educational context, 
the former measure usually indicates the ability of a person 
and the latter the difficulty of an item. In medical contexts, 
the former measure indicates the person’s perception of the 
condition of their health and the latter indicates the degree 
of severity conveyed by each item.61,65
Rasch models address the weaknesses of traditional 
approaches to measurement (the classic test theory) by 
yielding to measurements of latent dimensions which 
are objective and based on the principles of fundamental 
measurement.66,67 In other words, item calibrations that are 
independent of the characteristics of the individuals are 
produced and individuals are measured independently of 
the characteristics of the items. Fundamental measurement 
is taken for granted in the physical sciences, whereas in 
social sciences raw scores and the sum or means of these 
scores are typically considered as “measures” of a dimen-
sion independently of whether or not they conform to the 
principles of fundamental measurement.68 The measures 
obtained by means of application of the Rasch model have 
the following measurement properties: 1) linearity – the 
combinations (ie, sum, mean, etc) relating to the raw scores 
given by the participants using a categorical or rating 
response scale do not constitute an interval measurement 
scale due to the nonlinear metric nature of this procedure;62 
on the contrary, the unit of measurement (logit) defined by 
means of application of Rasch models (logit) and derived 
from the logarithmic form of the model has the same con-
stant value all along the continuum of the latent dimension; 
2) specific objectivity – the relationship between stimulus 
parameters defined by the application of a Rasch model is 
not influenced by subject parameters and vice versa; and 3) 
stochastic independence – the probability associated with 
a pattern of responses given by a subject n to the stimulus 
i is the product of the response probabilities given to each 
of the i stimuli.
Technical notes
All the statistical analyses were performed using the 
R software.69 The Rasch analysis was conducted using the 
Partial Credit Model by Masters70 by means of the eRm pack-
age.71 For Rasch Fit statistics (in order to flag items which did 
not fit), we used the infit-t statistics (namely, values out of the 
±2 range, as suggested by Wright and Linacre,72 Linacre,73 
Smith,74 Linacre),75 and the Chisq statistical probability (ie, 
P,0.05, as suggested by Bland and Altman).76 As an index 
of the reliability of the instrument, we used the Person 
Separation Reliability Index (PSRI)51 which is the Rasch 
equivalent of the Cronbach’s α. It ranges between 0 and 1; 
the closer its value is to 1, the greater is the probability that 
the differences among the participants’ measures express 
actual differences in the status of the participants along the 
three dimensions.
Results
screening of the 82 items for each 
dimension (impairment to health, risks 
involved, degree of commitment to the 
Treatment)
The fit of our initial 82 items to the Rash model was assessed. 
Each item was evaluated separately for the three dimensions 
(H, R, T) using the two exclusion criteria described above 
(infit-t statistics: out of the range ±2; Chisq: P,0.05). This 
allowed us to eliminate the items with a bad fit, thus improv-
ing the measurement properties of the final questionnaire. 
Sixty-one of the initial 82 items (74%) turned out to have 
a good fit with the impairment to Health scale, 65 of the 
initial 82 items (79%) had a good fit with the Risk scale, and 
69 (84%) had a good fit with the degree of commitment to the 
Treatment scale. The complete list of items and their scaling 
values (Location) is reported in Table S1, where the gray 
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background indicates misfit items, that is, those that were 
then eliminated from the subsequent analyses. The scaling 
values (reported in the “Location” columns) express the 
position of the items on the three scales relating to the three 
dimensions (H, R, T). In order to make the interpretation 
of these values easier and to make it possible to compare 
the three dimensions, the scaling values were adjusted so 
that the minimum value for each dimension was zero. The 
PSRI also turned out to be good for all three dimensions 
(H=0.951, R=0.938, T=0.947). The significant number of 
items with a good fit (61–69) in addition to the high values 
of the PSRI proves that most of the items used in the initial 
questionnaire were valuable for the assessment of the three 
target dimensions in that they satisfied the properties of the 
fundamental measurement. This also means that the result-
ing subset of items (after exclusion) constitutes a valuable 
item bank.
Figure 1 shows an example of the location of some of 
the information along the three dimensions (for the com-
plete verbal formulation of the items indicated in Figure 1 
by the alpha–numeric initials and for the complete list of 
items selected as having a good fit with each of the three 
dimensions, see Table S1). The three scales in Figure 1 give 
an idea of how the items were associated with a varying 
perception of severity relating to state of health (scale on 
the left), the risks involved (central scale), and the degree of 
commitment required by the treatment (scale on the right) 
and how their relative position shifted between dimensions. 
This triple rating for the same item represents a further 
development of a well-known Rasch approach which has 
been used for a long time in health care studies65,77–81 and 
has been recently applied specifically in studies concerning 
a cancer scenario.82–86
Analysis of the scaling values based on 
the structure of the items
Independent of the content of the items, we analyzed whether 
their position along the three dimensions (ie, the scaling val-
ues) also depended on their structure. The three aspects that 
were considered (as described in the “Introduction” section) 
were: Communication Type (Bipolar, B vs Unipolar, U), 
Polarity (positive, P, negative, N, or no mention of either 
of the poles, NN), and Quantity (numerically expressed 
quantity, NM; qualitatively expressed quantity, QL; vaguely 
expressed quantity, VG; no quantity, NO).
An ANOVA was performed on each dimension to test 
the effect of the three variables: Communication Type 
(B, U), Polarity (SN, VN, NN), and Quantity (NM, QL, VG, 
NO). This was done after having verified the normality and 
homoscedasticity of the distributions (by means of Shapiro 
and Levene tests, respectively). Communication Type 
turned out to be significant in two out of the three dimen-
sions, H (F
(1, 56)
=19.603, P,0.0001) and R (F
(1, 60)
=5.017, 
P=0.028) – see the top graphs in Figure 2. In both cases, the 
use of opposites in communication (B) was associated with 
higher localizations on the scales, indicating the perception 
of a more severe state of health and greater risks.
Polarity turned out to be significant for all three dimen-
sions (H: F
(1, 56)
=14.708, P,0.0001; R: F
(1, 60)
=13.298, 
P,0.0001; T: F
(1, 60)
=9.567, P=0.0002). The non-polarized 
information (NN) resulted in similar estimations of the 
perceived severity of the condition of health, the risk, 
Figure 1 The scales relating to ten of the items with a good fit for the three dimensions: impairment to Health (H), Risks involved (R), and the degree of commitment 
required by the Treatment (T). For the complete list of the items fitting in with each of the three dimensions, see Table S1.
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Figure 2 effect plots for Type of communication (B or U) and Polarity (Vn, sn, and nn) resulting from the AnOVA described in the text. Bars represent the 95% ci. 
contrasts (Bonferroni) and cohen’s effect size (d) values are reported within each plot.
Abbreviations: B, bipolar; nn, neither very negative nor slightly negative; sn, slightly negative; U, unipolar; Vn, very negative.
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and commitment involved relating to the SN information, 
and both were significantly greater than the results for the 
VN communication type (Figure 2). No significant effect 
emerged for the Quantity variable, either as a main effect or 
in interaction with other variables.
We also explored whether there was a significant asso-
ciation among these three variables – Communication Type 
(B, U), Polarity (VN, SN, NN), and Quantity (NM, QL, VG, 
NO) – and the Exclusion/Inclusion of an item from the selection 
described in the “Screening of the 82 items for each dimension 
(impairment to Health, Risks involved, degree of commitment 
to the Treatment)” section in the “Results” section.
Mosaic plots were used to represent and study these 
associations (Figure 3). A mosaic plot represents the 
frequencies of a contingency table by means of the size of 
the tiles; the interaction between variables is evaluated by 
means of the asymmetrical nonalignment of the tiles, and 
the significance of the difference between the observed 
and expected frequencies according to a specific model is 
determined by means of the color of the tiles. In our case, 
the model tested was a log-linear model of independence 
between variables. As shown in Figure 3, no significant asso-
ciation emerged between the frequency of Excluded (E) or 
Included (I) items and the various levels of Communication 
Type or Polarity. The only significant association concerned 
Quantity: as the blue tiles indicate (Figure 3, mosaic to the 
right), the items where quantity was expressed by means 
of numbers (NM) were particularly frequent in the case of 
Excluded items.
The relationship among the values for the 
h, r, and T dimensions and the relative 
conversion table
The subset of 53 items that had a good fit with all three dimen-
sions was used to study the relationships among the three 
dimensions. In all cases, the linear function models turned 
out to have the best fit to our data (ie, a simpler function and 
higher R2). The fits of the logarithmic, power, and exponen-
tial functions were also tested. The significant relationships 
among H, R, and T are reported in Table 1.
Six linear functions were obtained (H=f(R), R=f(H), 
H=f(T), T=f(H), R=f(T), T=f(R)). The average between 
Table 1 linear models describing the relationships among the dimensions: health (h), risks (r), and commitment to the Treatment (T)
Relationship Estimate Standard error t value Pr(.|t|) Multiple R2
r–h
h–r
0.768
0.898
0.072
0.084
10.672 1.34e-14*** 0.690
T–h
h–T
0.678
0.968
0.068
0.098
9.883 1.92e-13*** 0.657
T–r
r–T
0.671
0.820
0.084
0.103
7.908 2.03e-10*** 0.550
Note: ***P,0.001.
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Figure 3 Mosaic plots showing the frequency of e and i items for the three axes (h, r, T) based on communication Type (mosaic on the left), Polarity (central mosaic), 
and Quantity (mosaic on the right). The two levels for communication Type are B and U. The three levels for Polarity are Vn, sn, and nn. The four levels of Quantity are 
nM, Ql, Vg, and nO. The color of the tiles corresponds to Pearson residuals and the bars to the right of each mosaic show which color corresponds to residuals greater 
than the cut-off points |2| (corresponding to a P,0.05).
Abbreviations: B, bipolar; e, excluded; i, included; nM, numerical; nn, neither very negative nor slightly negative; nO, no quantity; Ql, qualitative; sn, slightly negative; 
U, unipolar; Vg, vague; Vn, very negative.
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Table 3 example showing how the locations of the items described in Table s1 can be used to weigh the raw scores provided by a 
participant on the h scale (thus obtaining the scores reported in the fourth column) and how it is possible to estimate the scores in the 
other two dimensions (R and T) based on the regression functions in Table 2 (scores reported in the fifth and sixth columns)
Item H raw score H weight/location H weighted score 
(raw score × item 
weight/location)
From weighted H  
to weighted R
From weighted H  
to weighted T
B16 10 1.145 11.45 10.444 9.422
B40 9 0.839 7.551 6.899 6.229
B18 8 0.781 6.248 5.715 5.162
B27 7 0.656 4.592 4.210 3.805
U33 6 0.558 3.348 3.079 2.787
U34 5 0.541 2.705 2.494 2.260
B13 4 0.483 1.932 1.792 1.627
U16 3 0.418 1.254 1.175 1.072
B2 2 0.354 0.708 0.679 0.624
B3 1 0.000 0.000 0.036 0.045
Table 2 conversion functions that can be used to make estimates 
of participants’ responses on other scales
From To Functions
r h h=1.110×r - 0.040
T h s=1.221×T - 0.056
T r r=1.154×T - 0.034
h r r=0.909×h + 0.036
h T T=0.819×h + 0.045
r T T=0.866×R + 0.029
the two functions referring to the same two dimensions 
(eg, H=f(R) and R=f(H)) was used to calculate the conversion 
table presented in Table 2. By means of the functions reported 
in the table, it was possible to study a person’s responses on 
one scale and make a likely estimate of his/her responses on 
another scale.
For example, let us imagine that a doctor is going to 
communicate a certain set of information during a medical 
consultation. For the sake of simplicity, let us assume that 
the information is the one represented in Figure 1 (ie, relating 
to the ten items reported below in Table 3, column 1: Item). 
The doctor might ask the patient to rate his/her perception 
of the degree of impairment to his/her health based on the 
ten items of information provided, and we may assume that 
the ten raw scores given by the patient are those reported in 
Table 3, column 2. We already know from the results reported 
in Table S1 that each item has a certain “weight” (as defined 
by its location on the H dimension), so the doctor can use 
these location values to “correct” the raw score given by the 
person and then, based on these corrected values, come up 
with an evaluation of how the patient perceives the situation 
(Table 3, column 4). Furthermore, the doctor might use the 
functions reported in Table 2 to make a good estimate from 
the above-mentioned weighted score for H regarding the 
patient’s perception of the risks involved (R) and the com-
mitment required for the treatment (T), that is, estimate the 
values in Table 3, columns 5 and 6.
Table S1 shows the item bank. A doctor might select 
some elements (it is not necessary for the doctor to use all 
the items) out of the whole set of items listed and use them 
in the context of doctor–patient communications. In this 
way, the doctor will have a good idea a priori concerning the 
potential impact of any given item. The weightings reported 
in Table S1 are based on the results of the present study, and 
thus reflect the characteristics relating to the participants 
who took part. The aim of the study was to find a procedure 
which would be useful in terms of assessing a patient’s 
understanding of any information given to him/her. If health 
practitioners have a better idea regarding the potential impact 
of any information given on a patient, this will help them 
to choose the best way of communicating, which will be 
beneficial to any therapy required.
Final discussion
Health care staff must ensure the quality of a patient’s 
understanding of any information provided in contexts 
where the patient is required to make decisions and be more 
effectively involved in the treatment process.87 Modeling 
the importance which people attach to the various pieces 
of information they receive seems to be a promising way 
to help doctors and health practitioners have a better under-
standing of how the patient sees his/her situation, enabling 
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them to provide more tailored assistance (for a review of 
the debate concerning the disclosure of information and 
the comprehension of disclosed information, see Cox88). 
It may also help medical staff to understand why patients 
decide to choose omission vs commission.17,89 The study 
presented in this paper adds to previous studies showing the 
advantage of using Rasch analyses to model psychological 
constructs related to health status.65,77–83 This model allows 
researchers to come up with robust (sample free) scalings 
of the items of information in terms of the psychological 
constructs of interest. These concern the condition of the 
patient’s health (H), the risks involved (R), and the degree 
of commitment to the treatment prescribed (T). The subset 
of items resulting from the scaling procedures performed 
as part of the study (Table S1) provides an example item 
bank that health care staff might be interested in utilizing 
and building on. Information concerning, for instance, the 
size of a nodule “might not seem to a doctor” to adequately 
convey the situation, since the size of a tumor is not neces-
sarily related to how serious it is. However, it is important 
to assess whether this is also the case “from the patient’s 
point of view”. If not, there is the risk of the situation seem-
ing extremely serious to the patient, leading to a potential 
misinterpretation. Being aware of this is an important point 
of departure.
When looked at from the point of view of the specific 
content considered in this study, our findings both consolidate 
previous results and add new knowledge. For instance, in the 
study carried out by Gavaruzzi et al,52 patients’ reactions to 
the information that a “benign tumor” had been found were 
not significantly different to their reactions in cases where no 
tumor was found. Our findings in a sense confirmed the very 
low perception of severity associated with communications 
of this type. The item in the questionnaire relating to the 
statement “The medical tests have revealed the presence of a 
small nodule” turned out to be at the extreme end of all of the 
three scales we referred to, since it elicited minimum values 
relating to impairment to health, the perception of risks, and 
the degree of commitment relating to the treatment prescribed 
(Figure 1 and Table S1). Regarding genetic predisposition, 
Gavaruzzi et al52 also found that doctor–patient communi-
cations concerning a “genetic predisposition” for a non-
tumorous illness had the same impact (in terms of decisions 
about active treatment) as communications concerning the 
presence of (and not only the predisposition for) a non-
tumorous illness. In our study, the item stating “This tumor 
is always connected to a genetic predisposition” (B13) 
elicited significantly lower values for all three dimensions 
(H=0.483, R=0.445, T=0.356) than the opposite item, “This 
tumor is never connected to a genetic predisposition” (B14; 
H=0.724, R=0.723, T=0.543). This suggests that a genetic 
predisposition was associated in the participants’ minds with 
a less serious condition.
If we then consider the structure of the items, our findings 
contribute valuable information to the question of the role 
that opposites might play in doctor–patient communication. 
We know that opposites have a special status in human cog-
nitive organization and that they are common to all natural 
languages and are intuitively and naturally understood and 
learnt.90–92 We also know that, when used in oncological 
consultations, they seem to improve the degree of under-
standing and satisfaction with how the information has been 
communicated and induce a greater degree of commitment 
and a more accurate perception of the severity of the disease 
and the risks involved.43 The results presented in the present 
paper confirm that the items which referred to opposites 
(Communication Type B in Figure 2) were generally asso-
ciated with a perception of greater severity in terms of H 
and R, and participants had a clearer idea regarding whether 
the information communicated was very negative (VN in 
Figure 2) or slightly negative (SN in Figure 2). Conversely, 
when information was provided qualitatively but without 
any mention of either of the poles (NN in Figure 2), the 
overall perception of the severity of the disease did not 
significantly differ from the information which referred to 
the negative pole. Paraphrasing previous findings concerning 
cancer patients’ understanding that “no news is not good 
news”,93 our results suggest that “non-polarized news is 
not good news”. Lastly, the verbal statements including 
quantitative expressions were frequently among the items 
which were excluded from the scalings resulting from the 
application of the Rasch model due to lack of fit. This sug-
gests that responses to those items did not presuppose the 
same cognitive dimension as those relating to the responses 
to the other type of items. This result adds to the literature 
on the specificity of using quantitative information.94–96
We are aware that any generalizations to real situa-
tions of the results discussed in this paper which were 
obtained with healthy volunteers in a simulated context 
have to be made with caution. Previous results have shown 
that people with life-threatening illnesses often interpret 
information concerning the risks of a particular course of 
treatment differently from healthy controls.87,97,98 However, 
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the suggestions regarding methodology put forward in 
this paper may stimulate future tests with real patients. 
The results indicate that it is possible to assess the impact 
of information conveyed by means of verbal statements 
(which may vary in terms of content and structure) in the 
context of doctor–patient communications. This would 
allow a better intentional modulation of any commu-
nication by health care staff (in terms of H, R, and T), 
enabling them to anticipate the impact on the patient. In 
addition to being useful in every context where doctors 
and patients interact, this type of knowledge may also be 
useful for the forms used for informed consent and for 
medical/pharmaceutical leaflets, especially with regard 
to side effects.
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Table S1 Complete list of the items used in the questionnaire and the corresponding classification of each item in terms of Polarity
Items Health Risk Treatment
ID Text Polarity Communication 
type
QuanQL Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location
1 Medical tests have shown the presence of a small nodule [le analisi hanno rivelato la presenza 
di un piccolo nodulo]
B sn Ql 493.889 469 0.206 0.7 0.329 488.687 469 0.256 0.62 0.289 450.010 469 0.728 -0.45 0.156
2 Medical tests have shown the presence of a large nodule [le analisi hanno rivelato la presenza 
di un grosso nodulo]
B Vn Ql 472.969 469 0.44 0.06 0.354 436.696 469 0.855 -1.21 0.399 464.345 469 0.552 -0.36 0.529
3 Medical tests have revealed the existence of a benign nodule [le analisi hanno rivelato la 
presenza di un nodulo benigno]
B sn Ql 495.598 469 0.191 0.76 0.000 498.017 469 0.171 0.56 0.000 456.560 469 0.651 -0.42 0.000
4 Medical tests have revealed the existence of a malignant nodule [le analisi hanno rivelato la 
presenza di un nodulo maligno]
B Vn Ql 439.506 469 0.832 -1.14 0.601 393.869 469 0.995 -1.84 0.589 441.653 469 0.813 -0.9 0.676
5 The Magnetic resonance (Mr) scan has revealed some nodules localized in a circumscribed 
region of your body [la risonanza magnetica ha rivelato la presenza di alcuni noduli localizzati in 
una zona circoscritta del tuo corpo]
B sn Ql 514.008 469 0.074 1.47 0.446 493.557 469 0.209 0.75 0.676 475.809 469 0.404 0.03 0.410
6 The Magnetic resonance (Mr) scan has revealed some nodules in various regions of your body 
[la risonanza magnetica ha rivelato la presenza di alcuni noduli diffusi in varie zone del tuo 
corpo]
B Vn Ql 413.112 469 0.97 -1.64 0.730 389.203 469 0.997 -2.17* 0.579 434.567 469 0.871 -1 0.556
7 This type of tumor is common [Questo tipo di tumore è comune] B sn Ql 421.369 469 0.944 -1.76 0.525 411.818 469 0.973 -2.13* 0.482 411.818 469 0.973 -2.04* 0.422
8 This type of tumor is rare [Questo tipo di tumore è raro] B Vn Ql 448.275 469 0.747 -0.38 0.769 400.705 469 0.99 -1.7 0.673 442.304 469 0.807 -0.99 0.549
9 This tumor is easy to treat [Questo tumore è facilmente curabile] B sn Ql 569.369 469 0.001* 3.60* 0.593 544.502 469 0.009* 2.91* 0.566 488.687 469 0.256 0.68 0.478
10 This tumor is hard to treat [Questo tumore è difficilmente curabile] B Vn Ql 454.834 469 0.672 -0.18 0.826 389.203 469 0.997 -1.4 0.747 448.553 469 0.744 -0.52 0.630
11 This type of tumor has a slow progression and takes a long time before it becomes serious 
enough to cause death [Questo tumore ha una progressione lenta (impiega molto tempo a 
diventare così grave da condurre alla morte)]
B sn Ql 459.522 469 0.614 -0.27 0.706 435.652 469 0.863 -1.22 0.667 440.653 469 0.822 -0.61 0.484
12 This type of tumor has a quick progression and takes very little time to become serious enough 
to cause death [Questo tumore ha una progressione veloce (impiega poco tempo a diventare 
così grave da condurre alla morte)]
B Vn Ql 447.808 469 0.752 -0.33 0.899 414.305 469 0.967 -0.95 0.918 412.693 469 0.971 -0.69 0.791
13 This tumor is always linked to a genetic predisposition [Questo tumore è sempre connesso con 
una predisposizione genetica]
B Vn Ql 442.838 469 0.802 -1.22 0.483 436.567 469 0.856 -1.21 0.445 429.872 469 0.902 -1.95 0.356
14 This tumor is never linked to a genetic predisposition [Questo tumore non è mai connesso con 
una predisposizione genetica]
B sn Ql 549.472 469 0.006* 0.91 0.724 502.320 469 0.139 0.66 0.723 427.955 469 0.913 -1.13 0.543
15 This tumor is associated with high survival rates [Questo tumore è associato ad alti tassi di 
sopravvivenza]
B sn Ql 477.257 469 0.386 0.25 0.332 494.904 469 0.197 0.88 0.323 433.580 469 0.878 -1.36 0.232
16 This tumor is associated with low survival rates [Questo tumore è associato a bassi tassi di 
sopravvivenza]
B Vn Ql 483.495 469 0.312 -0.31 1.145 441.543 469 0.814 -0.47 1.110 401.697 469 0.989 -0.75 0.842
17 This treatment will cure this tumor, ie, it will eliminate all of the tumor cells [Questo 
trattamento curerà il tumore, vale a dire che eliminerà tutte le cellule tumorali]
B sn nO 499.428 469 0.16 0.81 0.355 465.957 469 0.531 -0.21 0.241 448.737 469 0.742 -0.71 0.468
18 This treatment is palliative in nature, ie, it eliminates the symptoms associated with the tumor 
[Questo trattamento è palliativo, vale a dire che eliminerà i sintomi associati al tumore]
B Vn nO 466.417 469 0.525 -0.61 0.781 487.719 469 0.266 -0.09 0.712 477.989 469 0.377 0.13 0.584
19 This treatment has high efficacy [Questo trattamento ha un’alta efficacia] B sn Ql 454.917 469 0.671 -0.26 0.556 461.716 469 0.586 -0.2 0.403 426.835 469 0.919 -1.54 0.369
20 This treatment has low efficacy [Questo trattamento ha una bassa efficacia] B Vn Ql 427.588 469 0.915 -1.3 0.517 441.543 469 0.814 -1.15 0.622 421.867 469 0.942 -1.11 0.469
21 This treatment is necessary [Questo trattamento è necessario] B Vn nO 395.606 469 0.994 -2.4* 0.493 393.869 469 0.995 -2.6* 0.536 380.024 469 0.999 -2.18* 0.531
22 This treatment is advisable [Questo trattamento è consigliabile] B sn nO 480.308 469 0.349 0.58 0.433 462.415 469 0.577 -0.08 0.617 470.950 469 0.466 0.05 0.524
23 The standard treatment for this tumor has minor adverse side effects [il trattamento per questo 
tumore hai dei lievi effetti collaterali]
B sn Ql 411.361 469 0.974 -2.16* 0.413 413.520 469 0.969 -2.07* 0.525 416.783 469 0.96 -1.94 0.544
24 The standard treatment for this tumor has severe adverse side effects [il trattamento per 
questo tumore ha dei seri effetti collaterali]
B Vn Ql 421.620 469 0.943 -1.73 0.836 363.553 469 0.999 -2.38* 0.792 436.823 469 0.854 -0.75 0.819
25 The probability of adverse side effects linked to the treatment is very low [la probabilità di 
effetti collaterali associati al trattamento per questo tumore è molto bassa]
B sn Ql 406.417 469 0.983 -2.32* 0.461 419.786 469 0.95 -1.82 0.349 427.026 469 0.918 -1.37 0.349
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Table S1 Complete list of the items used in the questionnaire and the corresponding classification of each item in terms of Polarity
Items Health Risk Treatment
ID Text Polarity Communication 
type
QuanQL Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location
1 Medical tests have shown the presence of a small nodule [le analisi hanno rivelato la presenza 
di un piccolo nodulo]
B sn Ql 493.889 469 0.206 0.7 0.329 488.687 469 0.256 0.62 0.289 450.010 469 0.728 -0.45 0.156
2 Medical tests have shown the presence of a large nodule [le analisi hanno rivelato la presenza 
di un grosso nodulo]
B Vn Ql 472.969 469 0.44 0.06 0.354 436.696 469 0.855 -1.21 0.399 464.345 469 0.552 -0.36 0.529
3 Medical tests have revealed the existence of a benign nodule [le analisi hanno rivelato la 
presenza di un nodulo benigno]
B sn Ql 495.598 469 0.191 0.76 0.000 498.017 469 0.171 0.56 0.000 456.560 469 0.651 -0.42 0.000
4 Medical tests have revealed the existence of a malignant nodule [le analisi hanno rivelato la 
presenza di un nodulo maligno]
B Vn Ql 439.506 469 0.832 -1.14 0.601 393.869 469 0.995 -1.84 0.589 441.653 469 0.813 -0.9 0.676
5 The Magnetic resonance (Mr) scan has revealed some nodules localized in a circumscribed 
region of your body [la risonanza magnetica ha rivelato la presenza di alcuni noduli localizzati in 
una zona circoscritta del tuo corpo]
B sn Ql 514.008 469 0.074 1.47 0.446 493.557 469 0.209 0.75 0.676 475.809 469 0.404 0.03 0.410
6 The Magnetic resonance (Mr) scan has revealed some nodules in various regions of your body 
[la risonanza magnetica ha rivelato la presenza di alcuni noduli diffusi in varie zone del tuo 
corpo]
B Vn Ql 413.112 469 0.97 -1.64 0.730 389.203 469 0.997 -2.17* 0.579 434.567 469 0.871 -1 0.556
7 This type of tumor is common [Questo tipo di tumore è comune] B sn Ql 421.369 469 0.944 -1.76 0.525 411.818 469 0.973 -2.13* 0.482 411.818 469 0.973 -2.04* 0.422
8 This type of tumor is rare [Questo tipo di tumore è raro] B Vn Ql 448.275 469 0.747 -0.38 0.769 400.705 469 0.99 -1.7 0.673 442.304 469 0.807 -0.99 0.549
9 This tumor is easy to treat [Questo tumore è facilmente curabile] B sn Ql 569.369 469 0.001* 3.60* 0.593 544.502 469 0.009* 2.91* 0.566 488.687 469 0.256 0.68 0.478
10 This tumor is hard to treat [Questo tumore è difficilmente curabile] B Vn Ql 454.834 469 0.672 -0.18 0.826 389.203 469 0.997 -1.4 0.747 448.553 469 0.744 -0.52 0.630
11 This type of tumor has a slow progression and takes a long time before it becomes serious 
enough to cause death [Questo tumore ha una progressione lenta (impiega molto tempo a 
diventare così grave da condurre alla morte)]
B sn Ql 459.522 469 0.614 -0.27 0.706 435.652 469 0.863 -1.22 0.667 440.653 469 0.822 -0.61 0.484
12 This type of tumor has a quick progression and takes very little time to become serious enough 
to cause death [Questo tumore ha una progressione veloce (impiega poco tempo a diventare 
così grave da condurre alla morte)]
B Vn Ql 447.808 469 0.752 -0.33 0.899 414.305 469 0.967 -0.95 0.918 412.693 469 0.971 -0.69 0.791
13 This tumor is always linked to a genetic predisposition [Questo tumore è sempre connesso con 
una predisposizione genetica]
B Vn Ql 442.838 469 0.802 -1.22 0.483 436.567 469 0.856 -1.21 0.445 429.872 469 0.902 -1.95 0.356
14 This tumor is never linked to a genetic predisposition [Questo tumore non è mai connesso con 
una predisposizione genetica]
B sn Ql 549.472 469 0.006* 0.91 0.724 502.320 469 0.139 0.66 0.723 427.955 469 0.913 -1.13 0.543
15 This tumor is associated with high survival rates [Questo tumore è associato ad alti tassi di 
sopravvivenza]
B sn Ql 477.257 469 0.386 0.25 0.332 494.904 469 0.197 0.88 0.323 433.580 469 0.878 -1.36 0.232
16 This tumor is associated with low survival rates [Questo tumore è associato a bassi tassi di 
sopravvivenza]
B Vn Ql 483.495 469 0.312 -0.31 1.145 441.543 469 0.814 -0.47 1.110 401.697 469 0.989 -0.75 0.842
17 This treatment will cure this tumor, ie, it will eliminate all of the tumor cells [Questo 
trattamento curerà il tumore, vale a dire che eliminerà tutte le cellule tumorali]
B sn nO 499.428 469 0.16 0.81 0.355 465.957 469 0.531 -0.21 0.241 448.737 469 0.742 -0.71 0.468
18 This treatment is palliative in nature, ie, it eliminates the symptoms associated with the tumor 
[Questo trattamento è palliativo, vale a dire che eliminerà i sintomi associati al tumore]
B Vn nO 466.417 469 0.525 -0.61 0.781 487.719 469 0.266 -0.09 0.712 477.989 469 0.377 0.13 0.584
19 This treatment has high efficacy [Questo trattamento ha un’alta efficacia] B sn Ql 454.917 469 0.671 -0.26 0.556 461.716 469 0.586 -0.2 0.403 426.835 469 0.919 -1.54 0.369
20 This treatment has low efficacy [Questo trattamento ha una bassa efficacia] B Vn Ql 427.588 469 0.915 -1.3 0.517 441.543 469 0.814 -1.15 0.622 421.867 469 0.942 -1.11 0.469
21 This treatment is necessary [Questo trattamento è necessario] B Vn nO 395.606 469 0.994 -2.4* 0.493 393.869 469 0.995 -2.6* 0.536 380.024 469 0.999 -2.18* 0.531
22 This treatment is advisable [Questo trattamento è consigliabile] B sn nO 480.308 469 0.349 0.58 0.433 462.415 469 0.577 -0.08 0.617 470.950 469 0.466 0.05 0.524
23 The standard treatment for this tumor has minor adverse side effects [il trattamento per questo 
tumore hai dei lievi effetti collaterali]
B sn Ql 411.361 469 0.974 -2.16* 0.413 413.520 469 0.969 -2.07* 0.525 416.783 469 0.96 -1.94 0.544
24 The standard treatment for this tumor has severe adverse side effects [il trattamento per 
questo tumore ha dei seri effetti collaterali]
B Vn Ql 421.620 469 0.943 -1.73 0.836 363.553 469 0.999 -2.38* 0.792 436.823 469 0.854 -0.75 0.819
25 The probability of adverse side effects linked to the treatment is very low [la probabilità di 
effetti collaterali associati al trattamento per questo tumore è molto bassa]
B sn Ql 406.417 469 0.983 -2.32* 0.461 419.786 469 0.95 -1.82 0.349 427.026 469 0.918 -1.37 0.349
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Items Health Risk Treatment
ID Text Polarity Communication 
type
QuanQL Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location
26 The probability of adverse side effects linked to the treatment is very high [la probabilità di 
effetti collaterali associati al trattamento per questo tumore è molto alta]
B Vn Ql 411.818 469 0.973 -1.35 0.705 434.567 469 0.871 -0.6 0.674 455.083 469 0.669 -0.15 0.557
27 The adverse side effects related to the standard treatment for this tumor have an immediate onset 
[gli effetti collaterali associati al trattamento per questo tumore hanno un’insorgenza immediata]
B Vn Ql 432.405 469 0.886 -1.57 0.656 431.329 469 0.893 -1.27 0.785 417.741 469 0.957 -1 0.513
28 The adverse side effects related to the standard treatment for this tumor have a delayed onset 
[gli effetti collaterali associati al trattamento per questo tumore hanno un’insorgenza ritardata 
nel tempo]
B sn Ql 385.691 469 0.998 -2.51* 0.566 415.414 469 0.964 -1.88 0.534 413.520 469 0.969 -1.68 0.549
29 The adverse side effects related to the standard treatment are temporary [gli effetti collaterali 
associati al trattamento per questo tumore sono temporanei]
B sn Ql 391.796 469 0.996 -3.06* 0.498 420.595 469 0.947 -1.87 0.524 401.697 469 0.989 -2.41* 0.521
30 The adverse side effects related to the standard treatment are permanent [gli effetti collaterali 
associati al trattamento per questo tumore sono permanenti]
B Vn Ql 409.896 469 0.977 -1.79 0.655 409.373 469 0.978 -1.61 0.530 477.014 469 0.389 0.59 0.526
31 This treatment requires a short period of time to complete [il trattamento ha una durata breve] B sn Ql 433.146 469 0.881 -1.47 0.393 439.389 469 0.833 -1.22 0.332 439.738 469 0.83 -1.01 0.260
32 This treatment requires a long period of time to complete [il trattamento ha una durata lunga] B Vn Ql 414.684 469 0.966 -2.09* 0.531 431.329 469 0.893 -1.24 0.719 403.471 469 0.987 -0.75 0.651
33 This treatment is administered in a single cycle [il trattamento prevede un unico ciclo di 
somministrazione]
B sn Ql 470.178 469 0.476 0.25 0.552 487.719 469 0.266 0.73 0.551 493.667 469 0.208 0.93 0.437
34 This treatment is administered over many cycles [il trattamento prevede molti cicli di 
somministrazione]
B Vn Ql 380.024 469 0.999 -2.53* 0.615 389.203 469 0.997 -2.57* 0.583 454.751 469 0.673 -0.16 0.430
35 This treatment is administered on an outpatient basis [il trattamento è somministrato in day 
hospital]
B sn nO 413.112 469 0.97 -2.02* 0.424 433.436 469 0.879 -1.3 0.452 466.647 469 0.522 -0.43 0.309
36 This treatment is administered on an inpatient basis [il trattamento prevede ricovero e degenza 
in ospedale]
B Vn nO 442.088 469 0.809 -0.76 0.658 433.146 469 0.881 -1.12 0.635 530.339 469 0.026* 0.77 0.591
37 During treatment, you can live by yourself, you will not need assistance [Durante il trattamento 
puoi gestirti autonomamente, non avrai bisogno di assistenza]
B sn Ql 404.273 469 0.986 -2.48* 0.206 410.401 469 0.976 -2.22* 0.238 422.353 469 0.94 -2.1* 0.289
38 During treatment, you will need assistance [Durante il trattamento avrai bisogno di assistenza] B Vn Vg 456.641 469 0.65 -0.51 0.506 430.692 469 0.897 -1.14 0.456 516.995 469 0.062 0.27 0.468
39 Once the whole treatment cycle is completed, you can live by yourself, you will not need 
assistance [Una volta che il trattamento è completato, potrai gestirti autonomamente, non avrai 
bisogno di assistenza]
B sn Ql 472.969 469 0.44 0.08 0.539 460.231 469 0.605 -0.16 0.523 442.196 469 0.808 -0.99 0.484
40 Once the whole treatment cycle is completed, you will need assistance [Una volta che il 
trattamento è completato, avrai bisogno di assistenza]
B Vn Vg 444.495 469 0.786 -0.95 0.839 415.053 469 0.965 -1.66 0.530 441.980 469 0.81 -0.59 0.780
41 During treatment, your lifestyle will remain identical to what it was before treatment [Durante 
il trattamento il tuo stile di vita non subirà cambiamenti (rimarrà identico a com’era prima del 
trattamento)]
B sn Ql 511.176 469 0.087 1.36 0.444 491.832 469 0.225 0.89 0.358 456.070 469 0.657 -0.31 0.424
42 During treatment, your lifestyle will differ from what it was before the treatment [Durante il 
trattamento il tuo stile di vita subirà dei cambiamenti (non potrà più essere com’era prima del 
trattamento)]
B Vn Vg 418.048 469 0.956 -1.28 0.584 418.048 469 0.956 -1.42 0.494 515.952 469 0.066 0.66 0.485
43 After treatment is completed, your lifestyle will go back to what it was prior to the disease 
[Dopo il trattamento il tuo stile di vita tornerà identico a com’era prima della malattia]
B sn Ql 526.423 469 0.034* 1.93 0.461 506.367 469 0.113 1.36 0.344 482.531 469 0.323 0.49 0.515
44 After treatment is completed, your lifestyle will change from what it was prior to the disease 
[Dopo il trattamento il tuo stile di vita subirà dei cambiamenti rispetto a com’era prima della 
malattia]
B Vn Vg 430.203 469 0.9 -0.94 0.687 448.182 469 0.748 -0.63 0.498 439.970 469 0.828 -0.68 0.458
45 The treatment does not impact on your ability to work (ie, during the treatment phase, you 
can keep working) [il trattamento, mentre lo fai, non avrà ripercussioni sulla tua possibilità di 
lavorare (durante il trattamento potrai continuare ad andare al lavoro)]
B sn Ql 428.316 469 0.911 -1.78 0.340 456.884 469 0.647 -0.73 0.252 446.571 469 0.765 -0.96 0.356
46 The treatment impacts on your ability to work (ie, during the treatment phase, you cannot 
go to work) [il trattamento, mentre lo fai, avrà ripercussioni sulla tua possibilità di lavorare 
(durante il trattamento non potrai andare a lavorare)]
B Vn Vg 393.869 469 0.995 -1.65 0.750 408.266 469 0.98 -1.84 0.637 441.653 469 0.813 -0.75 0.677
47 Once the entire treatment cycle is completed, the treatment will have no impact on your ability 
to work (you can return to work as you did before the disease) [Una volta che l’intero ciclo 
di trattamento è finito, non avrai ripercussioni sulla tua attività lavorativa (potrai tornare a 
lavorare come prima della malattia)]
B sn Ql 447.526 469 0.755 -0.74 0.264 436.823 469 0.854 -1.18 0.288 434.979 469 0.868 -1.24 0.304
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Table S1 (Continued)
Items Health Risk Treatment
ID Text Polarity Communication 
type
QuanQL Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location
26 The probability of adverse side effects linked to the treatment is very high [la probabilità di 
effetti collaterali associati al trattamento per questo tumore è molto alta]
B Vn Ql 411.818 469 0.973 -1.35 0.705 434.567 469 0.871 -0.6 0.674 455.083 469 0.669 -0.15 0.557
27 The adverse side effects related to the standard treatment for this tumor have an immediate onset 
[gli effetti collaterali associati al trattamento per questo tumore hanno un’insorgenza immediata]
B Vn Ql 432.405 469 0.886 -1.57 0.656 431.329 469 0.893 -1.27 0.785 417.741 469 0.957 -1 0.513
28 The adverse side effects related to the standard treatment for this tumor have a delayed onset 
[gli effetti collaterali associati al trattamento per questo tumore hanno un’insorgenza ritardata 
nel tempo]
B sn Ql 385.691 469 0.998 -2.51* 0.566 415.414 469 0.964 -1.88 0.534 413.520 469 0.969 -1.68 0.549
29 The adverse side effects related to the standard treatment are temporary [gli effetti collaterali 
associati al trattamento per questo tumore sono temporanei]
B sn Ql 391.796 469 0.996 -3.06* 0.498 420.595 469 0.947 -1.87 0.524 401.697 469 0.989 -2.41* 0.521
30 The adverse side effects related to the standard treatment are permanent [gli effetti collaterali 
associati al trattamento per questo tumore sono permanenti]
B Vn Ql 409.896 469 0.977 -1.79 0.655 409.373 469 0.978 -1.61 0.530 477.014 469 0.389 0.59 0.526
31 This treatment requires a short period of time to complete [il trattamento ha una durata breve] B sn Ql 433.146 469 0.881 -1.47 0.393 439.389 469 0.833 -1.22 0.332 439.738 469 0.83 -1.01 0.260
32 This treatment requires a long period of time to complete [il trattamento ha una durata lunga] B Vn Ql 414.684 469 0.966 -2.09* 0.531 431.329 469 0.893 -1.24 0.719 403.471 469 0.987 -0.75 0.651
33 This treatment is administered in a single cycle [il trattamento prevede un unico ciclo di 
somministrazione]
B sn Ql 470.178 469 0.476 0.25 0.552 487.719 469 0.266 0.73 0.551 493.667 469 0.208 0.93 0.437
34 This treatment is administered over many cycles [il trattamento prevede molti cicli di 
somministrazione]
B Vn Ql 380.024 469 0.999 -2.53* 0.615 389.203 469 0.997 -2.57* 0.583 454.751 469 0.673 -0.16 0.430
35 This treatment is administered on an outpatient basis [il trattamento è somministrato in day 
hospital]
B sn nO 413.112 469 0.97 -2.02* 0.424 433.436 469 0.879 -1.3 0.452 466.647 469 0.522 -0.43 0.309
36 This treatment is administered on an inpatient basis [il trattamento prevede ricovero e degenza 
in ospedale]
B Vn nO 442.088 469 0.809 -0.76 0.658 433.146 469 0.881 -1.12 0.635 530.339 469 0.026* 0.77 0.591
37 During treatment, you can live by yourself, you will not need assistance [Durante il trattamento 
puoi gestirti autonomamente, non avrai bisogno di assistenza]
B sn Ql 404.273 469 0.986 -2.48* 0.206 410.401 469 0.976 -2.22* 0.238 422.353 469 0.94 -2.1* 0.289
38 During treatment, you will need assistance [Durante il trattamento avrai bisogno di assistenza] B Vn Vg 456.641 469 0.65 -0.51 0.506 430.692 469 0.897 -1.14 0.456 516.995 469 0.062 0.27 0.468
39 Once the whole treatment cycle is completed, you can live by yourself, you will not need 
assistance [Una volta che il trattamento è completato, potrai gestirti autonomamente, non avrai 
bisogno di assistenza]
B sn Ql 472.969 469 0.44 0.08 0.539 460.231 469 0.605 -0.16 0.523 442.196 469 0.808 -0.99 0.484
40 Once the whole treatment cycle is completed, you will need assistance [Una volta che il 
trattamento è completato, avrai bisogno di assistenza]
B Vn Vg 444.495 469 0.786 -0.95 0.839 415.053 469 0.965 -1.66 0.530 441.980 469 0.81 -0.59 0.780
41 During treatment, your lifestyle will remain identical to what it was before treatment [Durante 
il trattamento il tuo stile di vita non subirà cambiamenti (rimarrà identico a com’era prima del 
trattamento)]
B sn Ql 511.176 469 0.087 1.36 0.444 491.832 469 0.225 0.89 0.358 456.070 469 0.657 -0.31 0.424
42 During treatment, your lifestyle will differ from what it was before the treatment [Durante il 
trattamento il tuo stile di vita subirà dei cambiamenti (non potrà più essere com’era prima del 
trattamento)]
B Vn Vg 418.048 469 0.956 -1.28 0.584 418.048 469 0.956 -1.42 0.494 515.952 469 0.066 0.66 0.485
43 After treatment is completed, your lifestyle will go back to what it was prior to the disease 
[Dopo il trattamento il tuo stile di vita tornerà identico a com’era prima della malattia]
B sn Ql 526.423 469 0.034* 1.93 0.461 506.367 469 0.113 1.36 0.344 482.531 469 0.323 0.49 0.515
44 After treatment is completed, your lifestyle will change from what it was prior to the disease 
[Dopo il trattamento il tuo stile di vita subirà dei cambiamenti rispetto a com’era prima della 
malattia]
B Vn Vg 430.203 469 0.9 -0.94 0.687 448.182 469 0.748 -0.63 0.498 439.970 469 0.828 -0.68 0.458
45 The treatment does not impact on your ability to work (ie, during the treatment phase, you 
can keep working) [il trattamento, mentre lo fai, non avrà ripercussioni sulla tua possibilità di 
lavorare (durante il trattamento potrai continuare ad andare al lavoro)]
B sn Ql 428.316 469 0.911 -1.78 0.340 456.884 469 0.647 -0.73 0.252 446.571 469 0.765 -0.96 0.356
46 The treatment impacts on your ability to work (ie, during the treatment phase, you cannot 
go to work) [il trattamento, mentre lo fai, avrà ripercussioni sulla tua possibilità di lavorare 
(durante il trattamento non potrai andare a lavorare)]
B Vn Vg 393.869 469 0.995 -1.65 0.750 408.266 469 0.98 -1.84 0.637 441.653 469 0.813 -0.75 0.677
47 Once the entire treatment cycle is completed, the treatment will have no impact on your ability 
to work (you can return to work as you did before the disease) [Una volta che l’intero ciclo 
di trattamento è finito, non avrai ripercussioni sulla tua attività lavorativa (potrai tornare a 
lavorare come prima della malattia)]
B sn Ql 447.526 469 0.755 -0.74 0.264 436.823 469 0.854 -1.18 0.288 434.979 469 0.868 -1.24 0.304
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Items Health Risk Treatment
ID Text Polarity Communication 
type
QuanQL Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location
48 Once the entire treatment cycle is completed, the treatment will have an impact on your ability 
to work (you will not be able to return to work) [Una volta che l’intero ciclo di trattamento è 
finito, avrai ripercussioni sulla tua attività lavorativa (non potrai tornare a lavorare come prima 
della malattia)]
B Vn Vg 455.907 469 0.659 -0.61 0.751 442.838 469 0.802 -0.86 0.728 469.408 469 0.486 -0.45 0.720
1 Medical tests have shown the presence of a 0.5 inch long nodule (1.3 cm) [le analisi hanno 
rivelato la presenza di un nodulo di 1.3 cm]
U sn nM 498.523 469 0.167 0.91 0.039 507.396 469 0.107 1.17 0.294 519.861 469 0.052 1.62 0.090
2 Medical tests have shown the presence of a three inch long nodule (7.6 cm) [le analisi hanno 
rivelato la presenza di un nodulo di 7.6 cm]
U Vn nM 504.580 469 0.124 1.27 0.466 519.861 469 0.052 1.72 0.659 517.264 469 0.061 1.46 0.458
3 Medical tests demonstrated the existence of a nodule [le analisi hanno rivelato la presenza di 
un nodulo]
U nn Ql 477.095 469 0.388 0.22 0.203 497.767 469 0.173 0.89 0.212 534.729 469 0.019* 2.14* 0.366
4 The Magnetic resonance (Mr) scan has revealed some nodules in your body [la risonanza 
magnetica ha rivelato la presenza di alcuni noduli nel tuo corpo]
U nn Ql 551.641 469 0.005* 2.52* 0.515 557.526 469 0.003* 2.85* 0.553 496.544 469 0.183 0.7 0.414
5 This tumor affects 1 in a thousand people [Questo tipo di tumore colpisce 1 persona su 1,000] U sn nM 538.830 469 0.014* 2.56* 0.424 539.802 469 0.013* 2.38* 0.525 486.210 469 0.282 0.81 0.381
6 This tumor affects 1 in a million people [Questo tipo di tumore colpisce 1 persona 
su 1,000,000]
U Vn nM 562.016 469 0.002* 2.62* 0.524 545.968 469 0.008* 2.38* 0.574 554.245 469 0.004* 2.07* 0.443
7 This tumor is curable in 10% of all cases [Questo tumore è curabile nel 10% dei casi] U Vn nM 611.241 469 0.001* 0.88 0.784 523.969 469 0.04* 0.55 0.799 496.068 469 0.187 0.28 0.653
8 This tumor is curable in 80% of all cases [Questo tumore è curabile nell 80% dei casi] U sn nM 554.245 469 0.004* 2.86* 0.384 569.369 469 0.001* 3.18* 0.676 508.838 469 0.099 0.87 0.316
9 This type of tumor usually leads to death within two years of the time of diagnosis [Questo 
tumore generalmente conduce alla morte in 2 anni dalla diagnosi]
U Vn nM 525.568 469 0.036* 1.25 0.710 513.098 469 0.078 0.75 0.888 537.056 469 0.016* 0.68 0.684
10 This type of tumor usually leads to death within ten years of diagnosis [Questo tumore 
generalmente conduce alla morte in 10 anni dalla diagnosi]
U sn nM 538.830 469 0.014* 2.54* 0.535 611.241 469 0.001* 3.82* 0.457 538.830 469 0.014* 1.89 0.519
11 This tumor is determined by a specific genetic predisposition in 5 out of 5 cases [Questo 
tumore ha una predisposizione genetica in 5 casi su 5]
U Vn nM 528.270 469 0.03* 1.94 0.539 537.056 469 0.016* 2.4* 0.527 507.049 469 0.109 1.47 0.429
12 This tumor is determined by a specific genetic predisposition in 0 out of 5 cases [Questo 
tumore ha una predisposizione genetica in 0 casi su 5]
U sn nM 611.241 469 0.001 3.23* 0.611 611.241 469 0.001* 3.39* 0.670 611.241 469 0.001* 2.54* 0.624
13 This tumor has a 70% survival rate [Questo tumore ha un tasso di sopravvivenza del 70%] U sn nM 502.032 469 0.141 1.01 0.248 513.549 469 0.076 1.45 0.215 537.917 469 0.015* 1.75 0.221
14 This tumor has a 30% survival rate [Questo tumore ha un tasso di sopravvivenza del 30%] U Vn nM 494.563 469 0.2 0.55 0.557 463.034 469 0.569 0.26 0.610 477.744 469 0.38 0.4 0.623
15 This treatment will be of some help with this tumor [Questo trattamento sarà di qualche aiuto 
in questa situazione]
U nn Vg 481.667 469 0.333 0.33 0.415 478.480 469 0.371 0 0.567 493.778 469 0.207 0.15 0.505
16 This treatment has 70% efficacy rate [Questo trattamento ha un’efficacia del 70%] U sn nM 471.569 469 0.458 0.03 0.418 476.129 469 0.4 0.17 0.441 495.019 469 0.196 0.8 0.256
17 This treatment has a 30% efficacy rate [Questo trattamento ha un’efficacia del 30%] U Vn nM 508.107 469 0.103 1.05 0.596 494.449 469 0.201 0.89 0.567 488.201 469 0.261 0.74 0.444
18 This is a possible course of treatment [Questo è un possibile trattamento] U nn nO 486.396 469 0.28 0.51 0.350 461.327 469 0.591 -0.27 0.512 477.907 469 0.378 0.12 0.366
19 The standard treatment for this tumor has adverse side effects [il trattamento per questo 
tumore ha degli effetti collaterali]
U nn Vg 442.518 469 0.805 -0.97 0.427 468.948 469 0.492 -0.16 0.478 460.702 469 0.599 -0.4 0.398
20 The probability of adverse side effects relating to the treatment is 1 in 100,000 [la probabilità di 
effetti collaterali associati al trattamento per questo tumore è di 1 su 100.000]
U sn nM 486.396 469 0.28 0.55 0.319 517.813 469 0.059 1.53 0.224 510.972 469 0.088 1.16 0.274
21 The probability of adverse side effects relating to the treatment is 1 in 100 [la probabilità di 
effetti collaterali associati al trattamento per questo tumore è di 1 su 100]
U Vn nM 519.556 469 0.053 1.53 0.365 531.478 469 0.024* 2.17* 0.356 569.369 469 0.001* 2.74* 0.386
22 The adverse side effects related to the standard treatment for this tumor usually appear 1 day 
after treatment [gli effetti collaterali associati al trattamento per questo tumore generalmente 
appaiono un giorno dopo il trattamento]
U Vn nM 488.008 469 0.263 0.31 0.551 500.226 469 0.154 0.52 0.438 513.098 469 0.078 0.28 0.404
23 The adverse side effects related to the standard treatment for this tumor usually appear years 
after treatment [gli effetti collaterali associati al trattamento per questo tumore generalmente 
appaiono diversi anni dopo il trattamento]
U sn Ql 482.879 469 0.319 0.49 0.364 475.172 469 0.412 0.16 0.510 511.176 469 0.087 0.43 0.341
24 The duration of the adverse side effects related to the standard treatment varies over time 
[gli effetti collaterali associati al trattamento per questo tumore hanno una durata variabile nel 
tempo]
U nn Vg 467.184 469 0.515 -0.23 0.328 457.691 469 0.637 -0.38 0.450 479.638 469 0.357 -0.04 0.494
25 This treatment takes 15 days to complete [il trattamento si completa in 15 giorni] U sn nM 464.191 469 0.554 -0.19 0.261 495.481 469 0.192 0.83 0.172 530.339 469 0.026* 2.14* 0.462
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Items Health Risk Treatment
ID Text Polarity Communication 
type
QuanQL Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location
48 Once the entire treatment cycle is completed, the treatment will have an impact on your ability 
to work (you will not be able to return to work) [Una volta che l’intero ciclo di trattamento è 
finito, avrai ripercussioni sulla tua attività lavorativa (non potrai tornare a lavorare come prima 
della malattia)]
B Vn Vg 455.907 469 0.659 -0.61 0.751 442.838 469 0.802 -0.86 0.728 469.408 469 0.486 -0.45 0.720
1 Medical tests have shown the presence of a 0.5 inch long nodule (1.3 cm) [le analisi hanno 
rivelato la presenza di un nodulo di 1.3 cm]
U sn nM 498.523 469 0.167 0.91 0.039 507.396 469 0.107 1.17 0.294 519.861 469 0.052 1.62 0.090
2 Medical tests have shown the presence of a three inch long nodule (7.6 cm) [le analisi hanno 
rivelato la presenza di un nodulo di 7.6 cm]
U Vn nM 504.580 469 0.124 1.27 0.466 519.861 469 0.052 1.72 0.659 517.264 469 0.061 1.46 0.458
3 Medical tests demonstrated the existence of a nodule [le analisi hanno rivelato la presenza di 
un nodulo]
U nn Ql 477.095 469 0.388 0.22 0.203 497.767 469 0.173 0.89 0.212 534.729 469 0.019* 2.14* 0.366
4 The Magnetic resonance (Mr) scan has revealed some nodules in your body [la risonanza 
magnetica ha rivelato la presenza di alcuni noduli nel tuo corpo]
U nn Ql 551.641 469 0.005* 2.52* 0.515 557.526 469 0.003* 2.85* 0.553 496.544 469 0.183 0.7 0.414
5 This tumor affects 1 in a thousand people [Questo tipo di tumore colpisce 1 persona su 1,000] U sn nM 538.830 469 0.014* 2.56* 0.424 539.802 469 0.013* 2.38* 0.525 486.210 469 0.282 0.81 0.381
6 This tumor affects 1 in a million people [Questo tipo di tumore colpisce 1 persona 
su 1,000,000]
U Vn nM 562.016 469 0.002* 2.62* 0.524 545.968 469 0.008* 2.38* 0.574 554.245 469 0.004* 2.07* 0.443
7 This tumor is curable in 10% of all cases [Questo tumore è curabile nel 10% dei casi] U Vn nM 611.241 469 0.001* 0.88 0.784 523.969 469 0.04* 0.55 0.799 496.068 469 0.187 0.28 0.653
8 This tumor is curable in 80% of all cases [Questo tumore è curabile nell 80% dei casi] U sn nM 554.245 469 0.004* 2.86* 0.384 569.369 469 0.001* 3.18* 0.676 508.838 469 0.099 0.87 0.316
9 This type of tumor usually leads to death within two years of the time of diagnosis [Questo 
tumore generalmente conduce alla morte in 2 anni dalla diagnosi]
U Vn nM 525.568 469 0.036* 1.25 0.710 513.098 469 0.078 0.75 0.888 537.056 469 0.016* 0.68 0.684
10 This type of tumor usually leads to death within ten years of diagnosis [Questo tumore 
generalmente conduce alla morte in 10 anni dalla diagnosi]
U sn nM 538.830 469 0.014* 2.54* 0.535 611.241 469 0.001* 3.82* 0.457 538.830 469 0.014* 1.89 0.519
11 This tumor is determined by a specific genetic predisposition in 5 out of 5 cases [Questo 
tumore ha una predisposizione genetica in 5 casi su 5]
U Vn nM 528.270 469 0.03* 1.94 0.539 537.056 469 0.016* 2.4* 0.527 507.049 469 0.109 1.47 0.429
12 This tumor is determined by a specific genetic predisposition in 0 out of 5 cases [Questo 
tumore ha una predisposizione genetica in 0 casi su 5]
U sn nM 611.241 469 0.001 3.23* 0.611 611.241 469 0.001* 3.39* 0.670 611.241 469 0.001* 2.54* 0.624
13 This tumor has a 70% survival rate [Questo tumore ha un tasso di sopravvivenza del 70%] U sn nM 502.032 469 0.141 1.01 0.248 513.549 469 0.076 1.45 0.215 537.917 469 0.015* 1.75 0.221
14 This tumor has a 30% survival rate [Questo tumore ha un tasso di sopravvivenza del 30%] U Vn nM 494.563 469 0.2 0.55 0.557 463.034 469 0.569 0.26 0.610 477.744 469 0.38 0.4 0.623
15 This treatment will be of some help with this tumor [Questo trattamento sarà di qualche aiuto 
in questa situazione]
U nn Vg 481.667 469 0.333 0.33 0.415 478.480 469 0.371 0 0.567 493.778 469 0.207 0.15 0.505
16 This treatment has 70% efficacy rate [Questo trattamento ha un’efficacia del 70%] U sn nM 471.569 469 0.458 0.03 0.418 476.129 469 0.4 0.17 0.441 495.019 469 0.196 0.8 0.256
17 This treatment has a 30% efficacy rate [Questo trattamento ha un’efficacia del 30%] U Vn nM 508.107 469 0.103 1.05 0.596 494.449 469 0.201 0.89 0.567 488.201 469 0.261 0.74 0.444
18 This is a possible course of treatment [Questo è un possibile trattamento] U nn nO 486.396 469 0.28 0.51 0.350 461.327 469 0.591 -0.27 0.512 477.907 469 0.378 0.12 0.366
19 The standard treatment for this tumor has adverse side effects [il trattamento per questo 
tumore ha degli effetti collaterali]
U nn Vg 442.518 469 0.805 -0.97 0.427 468.948 469 0.492 -0.16 0.478 460.702 469 0.599 -0.4 0.398
20 The probability of adverse side effects relating to the treatment is 1 in 100,000 [la probabilità di 
effetti collaterali associati al trattamento per questo tumore è di 1 su 100.000]
U sn nM 486.396 469 0.28 0.55 0.319 517.813 469 0.059 1.53 0.224 510.972 469 0.088 1.16 0.274
21 The probability of adverse side effects relating to the treatment is 1 in 100 [la probabilità di 
effetti collaterali associati al trattamento per questo tumore è di 1 su 100]
U Vn nM 519.556 469 0.053 1.53 0.365 531.478 469 0.024* 2.17* 0.356 569.369 469 0.001* 2.74* 0.386
22 The adverse side effects related to the standard treatment for this tumor usually appear 1 day 
after treatment [gli effetti collaterali associati al trattamento per questo tumore generalmente 
appaiono un giorno dopo il trattamento]
U Vn nM 488.008 469 0.263 0.31 0.551 500.226 469 0.154 0.52 0.438 513.098 469 0.078 0.28 0.404
23 The adverse side effects related to the standard treatment for this tumor usually appear years 
after treatment [gli effetti collaterali associati al trattamento per questo tumore generalmente 
appaiono diversi anni dopo il trattamento]
U sn Ql 482.879 469 0.319 0.49 0.364 475.172 469 0.412 0.16 0.510 511.176 469 0.087 0.43 0.341
24 The duration of the adverse side effects related to the standard treatment varies over time 
[gli effetti collaterali associati al trattamento per questo tumore hanno una durata variabile nel 
tempo]
U nn Vg 467.184 469 0.515 -0.23 0.328 457.691 469 0.637 -0.38 0.450 479.638 469 0.357 -0.04 0.494
25 This treatment takes 15 days to complete [il trattamento si completa in 15 giorni] U sn nM 464.191 469 0.554 -0.19 0.261 495.481 469 0.192 0.83 0.172 530.339 469 0.026* 2.14* 0.462
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Items Health Risk Treatment
ID Text Polarity Communication 
type
QuanQL Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location
26 This treatment takes 1 year to complete [il trattamento si completa in 1 anno] U Vn nM 485.748 469 0.287 0.47 0.382 486.396 469 0.28 0.53 0.494 473.516 469 0.433 0.2 0.483
27 This treatment is administered in cycles [il trattamento è somministrato in cicli] U nn Vg 470.255 469 0.475 -0.23 0.411 472.034 469 0.452 -0.07 0.349 477.989 469 0.377 0.38 0.592
28 This treatment is administered in a medical facility [il trattamento è somministrato in una 
struttura ospedaliera]
U nn nO 459.364 469 0.616 -0.36 0.483 466.111 469 0.529 -0.15 0.355 475.411 469 0.409 0.21 0.330
29 During treatment, assistance might or might not be required [Durante il trattamento qualcuno 
ha, qualcun altro non ha bisogno di assistenza]
U nn Vg 448.182 469 0.748 -0.76 0.435 451.603 469 0.71 -0.64 0.526 471.724 469 0.456 0.02 0.441
30 Once the whole treatment cycle is completed, assistance might or might not be required [Una 
volta che il trattamento è completato qualcuno ha, qualcun altro non ha bisogno di assistenza]
U nn Vg 460.545 469 0.601 -0.28 0.420 456.722 469 0.649 -0.46 0.392 474.302 469 0.423 0.21 0.434
31 During treatment, your lifestyle might or might not be affected [Durante il trattamento il tuo 
stile di vita potrebbe subire dei cambiamenti (qualcuno riesce a fare la vita che faceva prima, 
qualche altro no)]
U nn Vg 468.948 469 0.492 -0.01 0.468 479.223 469 0.362 0.34 0.474 458.650 469 0.625 -0.13 0.498
32 After treatment is completed, your lifestyle might or might not change from what it was prior 
to the disease [Dopo il trattamento il tuo stile di vita potrebbe subire dei cambiamenti rispetto 
a com’era prima della malattia (qualcuno riesce a fare la vita che faceva prima, qualche altro no)]
U nn Vg 463.806 469 0.559 -0.17 0.521 487.053 469 0.273 0.31 0.369 472.034 469 0.452 0.43 0.431
33 The treatment might or not impact on your ability to work (during the treatment phase) 
[Il trattamento, mentre lo fai, potrebbe influire sulla tua possibilità di andare a lavorare 
(qualcuno durante il trattamento non riesce ad andare a lavorare, qualcuno invece sì)]
U nn Vg 468.564 469 0.497 -0.02 0.558 497.642 469 0.174 0.84 0.414 475.490 469 0.408 0.27 0.606
34 Once the entire treatment cycle is completed, the treatment might or not impact on your 
ability to work… [Una volta che l’intero ciclo di trattamento è finito, potresti avere (ma anche 
no) ripercussioni sulla tua attività lavorativa (qualcuno non riesce ad tornare a lavorare come 
prima, qualcuno invece sì)]
U nn Vg 471.646 469 0.457 -0.02 0.541 483.230 469 0.315 0.27 0.530 479.472 469 0.359 0.56 0.756
Notes: For each item, the results of two Rash Fit statistics are reported (Chisq and Infit-t). The gray background indicates the misfit items, that is, those that have been 
eliminated (the * indicates which of the two Rasch fit analysis results led to the item being eliminated).
Abbreviations: B, bipolar; nM, numerically expressed; nn, neither slightly negative nor very negative; nO, no quantity; Ql, qualitatively expressed; sn, slightly negative; 
Vg, vague quantity; Vn, very negative; U, unipolar.
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Items Health Risk Treatment
ID Text Polarity Communication 
type
QuanQL Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location Chisq df p-value Infit_t Location
26 This treatment takes 1 year to complete [il trattamento si completa in 1 anno] U Vn nM 485.748 469 0.287 0.47 0.382 486.396 469 0.28 0.53 0.494 473.516 469 0.433 0.2 0.483
27 This treatment is administered in cycles [il trattamento è somministrato in cicli] U nn Vg 470.255 469 0.475 -0.23 0.411 472.034 469 0.452 -0.07 0.349 477.989 469 0.377 0.38 0.592
28 This treatment is administered in a medical facility [il trattamento è somministrato in una 
struttura ospedaliera]
U nn nO 459.364 469 0.616 -0.36 0.483 466.111 469 0.529 -0.15 0.355 475.411 469 0.409 0.21 0.330
29 During treatment, assistance might or might not be required [Durante il trattamento qualcuno 
ha, qualcun altro non ha bisogno di assistenza]
U nn Vg 448.182 469 0.748 -0.76 0.435 451.603 469 0.71 -0.64 0.526 471.724 469 0.456 0.02 0.441
30 Once the whole treatment cycle is completed, assistance might or might not be required [Una 
volta che il trattamento è completato qualcuno ha, qualcun altro non ha bisogno di assistenza]
U nn Vg 460.545 469 0.601 -0.28 0.420 456.722 469 0.649 -0.46 0.392 474.302 469 0.423 0.21 0.434
31 During treatment, your lifestyle might or might not be affected [Durante il trattamento il tuo 
stile di vita potrebbe subire dei cambiamenti (qualcuno riesce a fare la vita che faceva prima, 
qualche altro no)]
U nn Vg 468.948 469 0.492 -0.01 0.468 479.223 469 0.362 0.34 0.474 458.650 469 0.625 -0.13 0.498
32 After treatment is completed, your lifestyle might or might not change from what it was prior 
to the disease [Dopo il trattamento il tuo stile di vita potrebbe subire dei cambiamenti rispetto 
a com’era prima della malattia (qualcuno riesce a fare la vita che faceva prima, qualche altro no)]
U nn Vg 463.806 469 0.559 -0.17 0.521 487.053 469 0.273 0.31 0.369 472.034 469 0.452 0.43 0.431
33 The treatment might or not impact on your ability to work (during the treatment phase) 
[Il trattamento, mentre lo fai, potrebbe influire sulla tua possibilità di andare a lavorare 
(qualcuno durante il trattamento non riesce ad andare a lavorare, qualcuno invece sì)]
U nn Vg 468.564 469 0.497 -0.02 0.558 497.642 469 0.174 0.84 0.414 475.490 469 0.408 0.27 0.606
34 Once the entire treatment cycle is completed, the treatment might or not impact on your 
ability to work… [Una volta che l’intero ciclo di trattamento è finito, potresti avere (ma anche 
no) ripercussioni sulla tua attività lavorativa (qualcuno non riesce ad tornare a lavorare come 
prima, qualcuno invece sì)]
U nn Vg 471.646 469 0.457 -0.02 0.541 483.230 469 0.315 0.27 0.530 479.472 469 0.359 0.56 0.756
Notes: For each item, the results of two Rash Fit statistics are reported (Chisq and Infit-t). The gray background indicates the misfit items, that is, those that have been 
eliminated (the * indicates which of the two Rasch fit analysis results led to the item being eliminated).
Abbreviations: B, bipolar; nM, numerically expressed; nn, neither slightly negative nor very negative; nO, no quantity; Ql, qualitatively expressed; sn, slightly negative; 
Vg, vague quantity; Vn, very negative; U, unipolar.
